TiumBio Co., Ltd. (KOSDAQ:321550)

Market Cap	320.15B +265.4%
Revenue (ttm)	12.29B +80.9%
Net Income	-17.36B
EPS	-640.00
Shares Out	29.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	435,462
Average Volume	795,167
Open	12,200
Previous Close	11,910
Day's Range	12,100 - 13,300
52-Week Range	2,970 - 13,480
Beta	0.46
RSI	60.07
Earnings Date	Apr 2, 2026

About TiumBio

TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company’s products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 321550

Financial Performance

In 2025, TiumBio's revenue was 12.29 billion, an increase of 80.92% compared to the previous year's 6.79 billion. Losses were -17.36 billion, -15.90% less than in 2024.